1 s was observed, with a trend toward an older
median age.
2 her country income, case patients had higher
median ages.
3 s encephalitis occurred in younger children (
median age,
1.7 years [interquartile range {IQR}, 0.1-6.
4 tudy period (01/2016-10/2016), 284 children (
median age 10.7 years, interquartile range 6.7-14.8) wer
5 Of the 651 children evaluated (
median age 11 years; median baseline eGFR of 53 ml/min p
6 We studied 38 children with NMDARE (
median age =
12.9 years, range =1-18) and a total of 82
7 data and no documented exclusion criterion (
median age,
12 years; interquartile range [IQR], 10-15 y
8 ears]; six men) and 12 participants with CF (
median age,
18 years [age range, 9-40 years]; eight men)
9 tions in 208,140 children under 7 years old (
median age =
2 years, minimum = 2, maximum = 7) by micro
10 Results In 10 healthy study participants (
median age,
21 years [age range, 18-27 years]; six men)
11 Women were
median age 22 years, 10.9% with HIV, 21.4% with Bacteria
12 resenting 11,349 infections across all ages (
median age =
22 years, minimum = 0.5, maximum = 100) det
13 recipients from HVTN 100 (n = 186, 60% male,
median age 23 years) enrolled between February 9, 2015,
14 ed 252 participants (210 vaccine/42 placebo;
median age 23 years; 43% female) between 9 February 2015
15 We identified 47 contacts,
median age 24 (3-75) years, with detectable SARS-CoV-2 b
16 A total of 57 adults (
median age 24 years [interquartile range = 20-29]), 53%
17 6, 2015 and from HVTN 111 (n = 56, 48% male,
median age 24 years) enrolled between June 21, 2016, and
18 d in the test cohort (center 2, 53 patients [
median age,
27 years; IQR, 22-35 years; 34 men]) using t
19 omes among 6,148 survivors of childhood ALL (
median age,
27.9 years; range, 5.9-61.9 years) diagnosed
20 During the study period, 306 pregnant women (
median age 29 years, 52.9% Hispanic or Latino) with CVD
21 Twenty women,
median age 29.7 years, enrolled in the study, with 10 in
22 rom center 1 (training cohort, 162 patients [
median age,
29 years; interquartile range {IQR}, 24-36 y
23 ol), and repair (regenerating gene 1beta) at
median ages 3, 14, and 28 months.
24 Most participants were in their early 30s (
median age:
33 years), of white (60%) or black (20%) rac
25 In sum, 23 227 patients (58% female;
median age 34 years [interquartile range 28-41]) were AR
26 Respondents (n = 723, 71% women,
median age 34; 85% white-ethnicity) were either followin
27 tion drug use-associated cases were younger (
median age,
34.5 vs 60 years) and more frequently had en
28 sting was performed on 972 participants with
median age 35.7 (interquartile range [IQR] 29.7-42.7) ye
29 nfections, patients with IDRIs were younger (
median age,
35 vs 46 years), more likely to be non-Hispa
30 ents with jejuno-ileal bowel CD; 31 females;
median age 36 (12-69) years] underwent 61 SSIS's for par
31 ome II criteria) were included (74% females,
median age 36 [interquartile range 28-50] years).
32 We included 307 women (
median age,
36 years) with valid histology results and t
33 RT (37.2% versus 62.8%), tended to be older (
median age 37 versus 33 years), and tended to have lower
34 -naive HBV-monoinfected patients: 49% males,
median age 38 years (range: 18-86), 32% HBeAg-positive,
35 Participant characteristics included
median age 39 years, median CD4 489 cells/mm3, and 94% h
36 val, were collected within 30 days (n = 338;
median age,
39 years; 210 men).
37 eters were compared with 19 HC participants (
median age,
39 years; IQR, 28-46 years; seven women).
38 e hundred forty-nine patients were included (
median age:
39 years, 38% men, 79% classical phenotype).
39 2 infants hospitalized for RV bronchiolitis (
median age,
4 months), we identified 4 distinct endotype
40 1397 adults (89%) living in 533 households (
median age 41 years; 43% male).
41 res were performed in 427 patients [F:M 1:1;
median age =
41 (12-95) yrs], through laparotomy (n = 15
42 s from 3 months to 3 years after the trauma [
median age:
41 years (Q1-Q3 24-54), median injury severi
43 336 subjects from the background population (
median age:
42.8 years [25th to 75th percentile: 33.1 to
44 Thirty men (
median age 43 years, 90% men who have sex with men) rece
45 One hundred thirty-four patients (59 men,
median age 43) completed the survey; 72 (54%) patients u
46 identified among 64 730 persons (51% female;
median age,
43 years [interquartile range, 22-62 years])
47 The cohort consisted of 3,829 patients (
median age 44 years; 30% women); 55% had type 1 MI, 32%
48 Participants (N = 1770; 80% female,
median age 45 years, median body mass index 47 kg/m) sel
49 erapy to 353 consecutive cT2 cN0/1 patients,
median age 47 years (range 22-76) treated from 2007 to 2
50 36) annually <=7 years (N = 646; 78% female,
median age 47 years, median BMI 46 kg/m).
51 sufficient data for this report (78% female;
median age 47 years; median body mass index 46 kg/m).
52 546 vehicle-traumatic AKI-RRT patients,
median age 47.6 years (interquartile range: 29.0-64.3) a
53 nts with PCR-confirmed SARS-CoV-2 infection (
median age,
47 years; 9 [50%] women), clinical presentat
54 f 5 patients (age range 2 months to 5 years;
median age 5.5 months).
55 Among 818 randomized patients (
median age,
5 years; 63% males), 816 completed the trial
56 Of 3520 participants (26.6% women,
median age 50 years), 2404 (68.5%) switched to TAF.
57 Results Evaluated were 156 women (
median age,
50 years; interquartile range, 44-63 years).
58 Results A total of 189 women (
median age,
52 years [interquartile range, 46-59 years])
59 teria, the cohort consisted of 747 patients (
median age 53 years, 47.5% women).
60 We included 333 cases (
median age 54 years; 14% women; 83% with suppressed HIV
61 ailable for 100 subjects with severe asthma (
median age 55 years; 42% males).
62 Results Among 45 202 women (
median age,
55 years; range, 25-90 years) with a BI-RADS
63 rosarcoma received ivosidenib (women, n = 8;
median age,
55 years; range, 30-88 years; 11 had receive
64 643 by using DM (August 2013 to July 2015) (
median age,
56 years; interquartile range, 49-66 years)
65 There were 610 766 individuals with HZ (
median age,
56.3 [IQR: 43.0, 68.7] years; 59.8% women; 7
66 ective study included 208 patients with SSc (
median age,
57 years; 167 women) evaluated between Janua
67 Among 479 patients who were randomized (
median age,
57 years; 44.3% female; 37.2% Hispanic/Latin
68 One-hundred and thirty-five adults (
median age:
57, M/F: 2.2/1) were screened.
69 In total, 258 patients (
median age 58 years, range 21-84) were identified with a
70 762 by using DBT (August 2015 to July 2017) (
median age,
58 years; interquartile range, 50-67 years),
71 Results Data from 782 patients (
median age,
59 years [interquartile range, 15 years]) fr
72 of whom were screened with DM (both groups:
median age,
59 years; interquartile range [IQR], 54-64 y
73 1078 underwent emergent coronary angiogram (
median age:
59.6 years, 78.3% males): 463 (42.9%) had an
74 Of the 302 randomized patients (
median age,
60 years [interquartile range, 55-65 years];
75 analyzed 47 407 participants from 5 cohorts (
median age,
60 years).
76 viation]) and 1225 matched control patients (
median age,
61 years +/- 16).
77 lts Fifty participants (25 men and 25 women;
median age,
61 years [interquartile range, 56-69 years];
78 individuals from Northern Germany (57% male,
median age 62 y), diet was assessed with a validated FFQ
79 atients were eligible (56% male; 44% female;
median age 62 years), 35 developed HCC (3.9%), and the m
80 The 231 included IE cases (187 [81%] men,
median age 62 years, 153 [66%] native valves) comprised
81 s Health Administration on 371,813 patients (
median age 62 years; 92.3% male) who received a diagnosi
82 were 437 women diagnosed with breast cancer (
median age,
62 years +/- 17 [standard deviation]) and 12
83 A total of 755,459 participants (
median age,
62 years [range, 32-91 years]; 53% female) w
84 20 COVID-19 patients with hyperinflammation (
median age,
62 years; 80.0% males; median PaO(2):FiO(2)
85 Of 9422 patients in the analytic cohort (
median age 63 years; 33% female; 75% White, 20% Black, 5
86 In the study period, 13,247 patients (
median age 63, F/M=3.6) had a focused parathyroidectomy
87 Of the 40 enrolled patients (78% men;
median age,
63 years), 33 (83%) completed treatment with
88 h a diagnosis of COVID-19 (858 [59.7%] male,
median age,
63 years), those receiving hydroxychloroquin
89 Results A total of 169 patients (
median age,
63 years; interquartile range, 55-73 years;
90 including 2280 African American men (26.1%) (
median age,
63.2 years) and 6446 non-Hispanic White men
91 There were 103 datasets used for training (
median age,
64 years; interquartile range [IQR], 11), 15
92 age, 68 years; IQR, 12), and 37 for testing (
median age,
64 years; IQR, 12).
93 Of the 352 patients (
median age,
65 years; 63% female; 22% black) studied, 35
94 rs) and 6446 non-Hispanic White men (73.9%) (
median age,
65.5 years), and the median follow-up was 7.
95 Results In a total of 183 participants (
median age 66 years, 80% male), 116 (63%) patients had i
96 Of 1530 patients (
median age 66 years; 58.2% men) receiving dialysis, 300
97 e randomized, 969 (99%) completed the trial (
median age,
66 [interquartile range {IQR}, 56-74] years;
98 atients with relapsed/refractory CLL or SLL (
median age,
66 years [range, 42-85 years]; median prior
99 Results A total of 1070 patients (
median age,
66 years; interquartile range, 54-75 years;
100 Thirteen men and 15 women with a
median age 67 years participated in the study.
101 163 formalin-fixed paraffin-embedded (FFPE,
median age 67, 39% women) samples, respectively.
102 Of the 203 participants (
median age,
68 [interquartile range {IQR}, 65-71] years;
103 uring hospitalization, 373 patients (14.2%) (
median age,
68 years [IQR, 56-78]; 33.5% female) were tr
104 d 236 patients (59 of 123 [25%] were female;
median age,
68 years).
105 uartile range [IQR], 11), 15 for validation (
median age,
68 years; IQR, 12), and 37 for testing (medi
106 of 194 metformin-treated diabetic patients (
median age:
68.6; males: 113 [58.2%]); 163 (84%) had acu
107 Most of these participants (1654 [95%];
median age 69 years) swallowed the Cytosponge successful
108 Of 614 patients (
median age 69 years, (IQR 25) and 62% male), 381 (62%) h
109 na, Spain and included 112 fresh frozen (FF,
median age 69, 44% women) and 163 formalin-fixed paraffi
110 Results: There were 75 men (
median age,
69 y; median serum PSA, 3.69 mug/L) with 232
111 record abstractions and available ICD codes (
median age,
69 years [interquartile range, 54 to 81 year
112 Results Sixty-five individuals (
median age,
69 years [range, 19-84 years]; 53 men) were
113 We included 295 biopsies in 278 patients (
median age,
69 years; 64.1% male; 44.7% had prior neopla
114 Fifty participants (
median age 7.3 years) were randomized and initiated trea
115 compared with immune-mediated encephalitis (
median age,
7.6 years [IQR, 4.6-12.4]).
116 In total, 96 patients (61 men;
median age,
70 years [range, 29-94]) were included, of w
117 A total of 102 participants (
median age,
70; range, 58-78 years; 60 women) were inclu
118 rst episodes of sepsis (17,886, 51%, female;
median age 71 years, interquartile range 57-82 years).
119 Of 10,254 prevalent RAS inhibitor users (
median age 72 years, 36% female) with new-onset eGFR <30
120 A total of 1 545 952 patients (58.0% women;
median age 72 years; interquartile range, 68-77 years) a
121 Six hundred four participants were screened (
median age 73 y, 42.7% male).
122 tients received ivosidenib plus azacitidine (
median age,
76 years; range, 61-88 years).
123 Two hundred thirty-three patients (69% men;
median age,
77 [69-83] years) underwent the study protoc
124 (3115 [51.4%] girls [sex unknown in seven],
median age 8 years [IQR 5-13]).
125 g primary Ross procedure tended to be older (
median age 8.6 years vs. 7.0 years; p = 0.10) and have a
126 data from 1,105 mothers and their children (
median age,
8.2 years; interquartile range, 6.6-9.1) fro
127 Of 728 TAVR patients, 112 (53.5% men;
median age,
81 years) underwent pacemaker implantation a
128 Among 503 patients who were randomized (
median age,
87 years; 298 [59%] women), 502 were analyze
129 Fifty-eight children (
median age,
9 years [interquartile range {IQR}, 5.7-14];
130 d degenerative valve disease; and had higher
median age-
adjusted Charlson score. EE more frequently i
131 Median age and frequency of comorbidities were similar,
132 The pooled sample included 252 745 women (
median age at baseline, 57 years) with 38% self-reportin
133 Median age at deep brain stimulation was 11.5 years (ran
134 months) and secondary glaucoma groups (47%,
median age at diagnosis = 3 years), respectively.
135 en were 12.2 and 12.6 years in the PCG (53%,
median age at diagnosis = 5 months) and secondary glauco
136 In the SEER database, the
median age at diagnosis of uveal melanomas was 63 (range
137 Median age at dialysis initiation was 64 years, 45% were
138 y participants of the Penn Medicine Biobank (
median age at enrollment 63 years, interquartile range 5
139 The
median age at enrollment was 3.2 months (interquartile r
140 Median age at first booking was 25 years (interquartile
141 Median age at HCT was 1.2 years.
142 The
median age at hypertension was approximately a decade ea
143 The
median age at IBD diagnosis was 55 years (range 29-85 ye
144 29% had AF, 21% required de novo pacemakers (
median age at implantation 37 years; IQR: 29 to 48 years
145 The
median age at initial presentation was 72.5 years, and 3
146 Median age at ITx was 7.7 years and weight was 23 kg.
147 aged 22 years (22 years before the estimated
median age at mild cognitive impairment onset of 44 year
148 The
median age at presentation for congenital cataracts that
149 The
median age at presentation of 35 children was 26 days (i
150 agnosis was 8 years (range, 1-22 years), and
median age at presentation of Coats-like exudative vitre
151 Median age at presentation was 2.8 years and median foll
152 The
median age at radical prostatectomy was 62 years.
153 Median age at surgery was 12 months (range 1-325 months,
154 INSTIs were 81% male and 50% nonwhite with a
median age at switch of 50 years, CD4+ T-cell count 512
155 Median age at time of RP diagnosis was 8 years (range, 1
156 Median age at transplant was 21.4 months (0.1-7.8 years)
157 Median age at vaccination (18.7 years) was older than ag
158 ng a certain pubertal stage earlier than the
median age for that stage.
159 Median ages for the cohorts ranged from 41.5 to 59.0 yea
160 The
median age in years (range) in MOGAD of 24 (2-65) was yo
161 The
median age (
interquartile range) at IPD due to serotypes
162 Median age (
IQR) was 50 (41, 57) years and 48.8% were ma
163 ssibly reflecting the young age of recruits (
median age &
lt;60 years), and raise questions about general
164 The
median age,
MUAC, and WLZ were 100 d (IQR: 69-145 d), 11
165 90 patients, with a
median age of 14 years (IQR 10-17), were enrolled.
166 , 431 YLPHIV and 93 youth without HIV with a
median age of 14.1 versus 13.9 years, respectively, were
167 530 patients (59% male) underwent TPVR at a
median age of 18.3 years (interquartile range [IQR]: 12.
168 3 (44.1%) individuals aged <=17 years with a
median age of 19 years (interquartile range, 10-32); 423
169 ht eyes (96 children) were identified with a
median age of 2.5 months (range, 1-7 months) at the time
170 in 30 (53%) of 57 affected individuals at a
median age of 22.5 years.
171 All patients were white females, with a
median age of 27 years (range 21-75) at diagnosis.
172 tudy population included 108 patients with a
median age of 28 days (range, 0 days to 17 years); 34% w
173 IBD patients were younger than NIC patients (
median age of 38 years vs. 50, P < 0.001).
174 y included 338 patients: 210 men (62%), with
median age of 39 years (interquartile range, 31-45 years
175 cross six CTG trials were 71% male and had a
median age of 45 years.
176 Results: With a
median age of 46 y, 95 patients were enrolled, half of t
177 e treated in the RGT were 73% male and had a
median age of 47 years.
178 ere 43% non-Hispanic black, 73% male, with a
median age of 48 years; 421 and 649 were included in the
179 In eight children who started ART at a
median age of 5.4 months (range, 2.0 to 11.1 months), 73
180 l of 7770 participants were enrolled, with a
median age of 50 years (interquartile range, 45-55 years
181 romal Alzheimer's disease was diagnosed at a
median age of 50.2 years (IQR 47.5-54.1), and Alzheimer'
182 Registry patients had a
median age of 51 years (range, 32 days to 92 years).
183 The 99 participants had a
median age of 51 years old; 67 were men, 31 had diabetes
184 Ninety patients were analyzed with a
median age of 57 years.
185 A total of 480,940 middle-aged adults (
median age of 58 years [range 38-73], 46% male, 95% whit
186 Seventy-six patients were enrolled with a
median age of 59 years (range, 40-76 years), and 35.5% h
187 from cohort B; 57 (49%) were female, with a
median age of 6.2 years (IQR 3.7-10.0).
188 two evaluable patients were enrolled, with a
median age of 60 years and a median of 3 prior therapies
189 ients of whom 427 [47%] were female and with
median age of 64 years [IQR 56-70, range 22-89] and medi
190 Allocated groups were balanced with a
median age of 65 years (IQR 60-68).
191 nantly male (63.9%) and White (93.2%) with a
median age of 65.
192 Sixty-three patients were included with a
median age of 66 years old.
193 with FASD by a multidisciplinary team at the
median age of 7.9 years were followed up by the same tea
194 The cohort had a
median age of 71.5 years (range, 38-97 years); 69% were
195 Fifty-one patients with a
median age of 72 years (range, 63-80 years) were include
196 e severity in 41 481 patients (48.7% female,
median age of 75 years [interquartile range, 64- 83]).
197 First infections appeared at a
median age of 8 (interquartile range, 6.0-11.7) months.
198 The study included 373 patients with
median age of 84 years (age range, 51-98 years; interqua
199 The remaining 1500 patients had a
median age of 86 (IQR 82-89) years of whom (845 [56%] re
200 The
median age of cases was 49.5 years (interquartile range
201 The
median age of diagnosis was 15 months (range; 5 months-1
202 The
median age of enrolled participants is 21 years (range 0
203 case households, 743 HHCs were enrolled; the
median age of HHCs was 33 (interquartile range, 22-49) y
204 The
median age of local cases was 8 years older than that of
205 a potentially fatal arrhythmic event with a
median age of onset of 7 years (95% CI, 6-11).
206 Median age of participants was 14 years (IQR 10-29) and
207 The
median age of participants was 62 years (IQR 56-69) in 2
208 The
median age of patients was 50 years (interquartile range
209 The
median age of patients was 53 years (interquartile range
210 The
median age of persons in the risk interval was 57.5 year
211 The
median age of presentation was 10 months.
212 The
median age of the 452 matched patients was 75 years (IQR
213 Results The
median age of the cohort was 64 years (interquartile ran
214 The
median age of the enrolled patients was 13 years (IQR 8-
215 The
median age of the patients at randomization was 67.8 yea
216 98 case patients, 79% of whom were male; the
median age of the patients was 21 years.
217 The
median age of the patients was 30 years and the male to
218 The
median age of the total population was 32.1 years at ent
219 The
median age (
Q1, Q3) at the final menstrual period was 48
220 % confidence interval, 29.2%-41.8%]) and the
median age shifted from 38.3 months to 23.7 months (P =
221 HPV vaccination was predicted to reduce the
median age-
standardised cervical cancer incidence in LMI
222 At enrolment, the
median age was 15 years (IQR 14-17), 52% of adolescents
223 The
median age was 17.0 years (interquartile range [IQR] = 9
224 The
median age was 2.4 years, 233 (79.8%) were in medical/su
225 The
median age was 2.8 years (interquartile range [IQR], 1.3
226 Participant
median age was 20 years (IQR:19,22).
227 Fifty-nine percent were male;
median age was 22 years (range, 8 days-80 years).
228 The
median age was 23 years (IQR 13 to 34) and 854 (78%) of
229 The
median age was 24 (interquartile range: 20-30) years.
230 Their
median age was 25 to 34 years.
231 The
median age was 25 years, the HIV prevalence was 7.2%, an
232 Among 91 patients, the
median age was 26 years (IQR, 11-47).
233 For the 515 HBsAg-positive women,
median age was 29 years, 92 (17.9%) were HBeAg positive,
234 The
median age was 3 years; 81.2% of the patients were 18 ye
235 The mothers'
median age was 30.0 years, and most mothers were medium
236 The
median age was 31 (IQR 28 to 40).
237 Participant
median age was 31 years, and 95% had 1 or more prior pre
238 The
median age was 34 years, and 407 (51.7%) were female.
239 Median age was 34 years; disease stage was I or III in 5
240 Of those with P. knowlesi, the
median age was 35 (interquartile range: 24-47) years, an
241 Median age was 35.5 years (range, 3-88).
242 The
median age was 36 months (interquartile range, 18-60): 1
243 riteria, the majority (61%) were inpatients,
median age was 37 years (IQR 30-43), 43% had a CD4 count
244 Most were male (82%) and the
median age was 38 years.
245 Median age was 40 years (IQR 35-48), CD4 cell count was
246 Median age was 41.9 years, 89% were HIV positive (+) (42
247 Median age was 45.3 years, and 82.3% were male.
248 Median age was 46 years (range 18 to 90 years), 68/106 (
249 Median age was 48 years with 13% (n = 64) above the age
250 Median nadir CD4 count was 246 cells/mm3;
median age was 48 years; 17% of participants were female
251 The
median age was 49 (range, 18-86) years, and 62% were >=
252 Median age was 49 years, 55.9% were lymph node negative,
253 Median age was 49 years, 93% were male, 51% black, 93% h
254 The
median age was 5 years, with 93.7% females and 77.6% Jew
255 The
median age was 5.9 years.
256 Among 7770 participants enrolled, the
median age was 50 years, 31% were female (natal sex), 43
257 Among 1076 adults with GBS infection,
median age was 52 years, 51% were male, and 89% had >=1
258 Part 1: Patients'
median age was 55 years; 31% were women, and 19% were bl
259 rs (58%) participated (from 22 sites); their
median age was 56 (interquartile range 47-62).
260 Median age was 57 [25%-75% 43-73] for men versus 52 [38-
261 Median age was 58 years (IQR, 52-65), median eGFR was 95
262 The
median age was 58 years and 52% of patients were men.
263 Median age was 58 years, 71% of patients were men, 84% h
264 Median age was 58, 82% were male, 78% had cirrhosis, mos
265 Median age was 59 years with a mean Elixhauser comorbidi
266 Median age was 59 years, and 45% of the patients had rec
267 The
median age was 6 y.
268 The
median age was 60 years old (interquartile range [IQR],
269 The
median age was 60 years, male to female ratio 1:2 and 75
270 Median age was 61 years, 86% were men, median left ventr
271 In this latter group, the
median age was 62 years (6-83).
272 31 patients in the study: 52.8% were female,
median age was 62 years (interquartile range [IQR] 46 to
273 The
median age was 62 years (range, 21-82 years).
274 Median age was 62 years, and 85% were men.
275 Median age was 63 years, and 56% of patients were male.
276 The
median age was 64 (56-79) and 57% of patients were femal
277 Median age was 64 years (IQR 57-70, range 36-85).
278 The
median age was 65 years (range, 40-90 years), 44 (43.1%)
279 Among 4,389 patients,
median age was 65 years with 44% women.
280 Median age was 65 years, and median disease duration was
281 omly assigned participants, 81.2% were male,
median age was 65.7 years, and median body mass index wa
282 44.6% were female, 66.3% were Black, and the
median age was 66 years (interquartile range, 56-75 yr).
283 The
median age was 66.4 years, with 59.6% men.
284 Median age was 67 y (range, 38-84 y), and 84% of all pat
285 ified and included in the TERAVOLT registry;
median age was 68.0 years (61.8-75.0) and the majority h
286 There were 223 males,
median age was 69 and histology was epithelioid in 184.
287 Median age was 69 years (range, 45-83).
288 Among hospitalized patients, the
median age was 69 years, and nearly all patients (96%) h
289 The
median age was 70 with 89% white, 59% female, median BMI
290 The
median age was 70.7 years; 50.9% were males; and 66.2% w
291 The
median age was 71 years (range, 60-88 years).
292 nalysis, we analyzed 39,121 CKD outpatients (
median age was 71 years, 54.7% were men, median eGFR was
293 The patients'
median age was 71, 61.8% were male, white (87.2%), had h
294 Median age was 71.0 years, 50.6% were male, median estim
295 Median age was 72 years (range 60-92 years; 38% >=75 yea
296 The
median age was 8.3 years, 115 patients (62%) were male,
297 The
median age was 80 years and 42.7% were male.
298 ients treated with tPA within 4.5 hours, the
median age was 80 years and 43.5% were male.
299 Median age was similar between trials at 64 or 65 years
300 Median age (
years) for week 130 desensitization success